ONLINE EDITION

26th March 2021

PROGRAM
12th MEETING OF THE EUROPE FORUM ON ANTIPHOSPHOLIPID ANTIBODIES
The 1st Virtual
Friday, March 26th, 2021

08.30-09.20 Welcome to 12th MEETING OF THE EUROPEAN FORUM ON ANTIPHOSPHOLIPID ANTIBODIES
  • Denis Wahl (France): General coordinator of the European Forum.
  • Ricard Cervera (Spain): The former General coordinator of the European Forum.
  • Aleksandra Djokovic (Serbia): President of the National Organizing Committee
  • Ljudmila Stojanovich (Serbia): Congress President
09.20-10.20 STATE OF THE ART LECTURES

Moderators: Graham Hughes (UK) Ricard Cervera (Spain)

09.20-09.40

APS/Hughes Syndrome – a personal history.

Graham Hughes (UK)

09.40-10.00

Lessons from CAPS registry.

Ricard Cervera (Spain)

10.00-10.20

Update on the New Antiphospholipid Syndrome Classification Criteria Development.

Stephane Zuily (France)

10.20-12.00 SCIENTIFIC SESSION 1: CLINICAL MANIFESTATIONS AND TREATMENT OF APS

Moderators: Denis Wahl (France) Ljudmila Stojanovich (Serbia) 

KEYNOTE LECTURES

10.20-10.40

Antiphospholipid syndrome and direct oral anticoagulants.

Denis Wahl (France)

10.40-11.00

The cutaneous manifestations precede severe vascular:  from the cross-section analysis of a national APS patients registry.

Ljudmila Stojanovich (Serbia)

11.00-11.20

Heart failure profile in autoimmune diseases – analysis of the Serbian antiphospholipid syndrome patients.

Aleksandra Djokovic et al. (Serbia)

ABSTRACT PRESENTATIONS

11.20-11.30

Should be older patients tested for antiphospholipid antibodies? 695 cases from the retrospective HIBISCUS series.

Belizna Cristina on behalf of HIBISCUS working group (France, Argentina, Serbia, Belgium, Spain, Italy, Russian Federation)

11.30-11.40

The management of thrombocytopenia in patients with Primary Antiphospholipid Syndrome.

Laura Andreoli (Italy)

11.40-11.50

Platelets indices and treatment in antiphospholipid syndrome patients.

Natasa Stanisavljevic (Serbia)

11.50-12.00

Thrombocytopenia in antiphospholipid syndrome longitudinal follow-up.

Tatjana Reshetnyak (Russian Federation)

12.00-12.10

CLOSING REMARKS

12.10-14.10     SCIENTIFIC SESSION 2: SEROLOGY AND NEW TESTS FOR APS

Moderators: Munther Khamashta (UAE), Vittorio Pengo (Italy)

KEYNOTE LECTURES

12.10-12.30

New insight in APS pathogenesis: cue for new diagnostic/therapeutic approach?

Pier Luigi Meroni (Italy)

12.30-12.50

Recognition and meaning of Lupus Anticoagulant.

Vittorio Pengo (Italy)

ABSTRACT PRESENTATION

12.50-13.00

Antiphospholipid antibodies negativisation in patients with antiphospholipid syndrome: a long-term follow-up multicenter study.

Massimo Radin (Italy)

13.00-13.10

Presence of immune complexes of IgG/IgM bound to B2-glycoprotein i in APS patients: report from a preliminary study to an international cohort.

Naranjo L.et al. (Spain, Serbia, Israel)

13.10-13.20

Molecular Profiling of Antiphospholipid Syndrome Patients: Type I Interferon Signature Heterogeneity among Disease Subsets.

Irene Cecchi (Italy)

13.20-13.30

Peptide Microarray based on R39-R43 of Domain I of β2-Glycoprotein I Determined Antigenic Specificity of Antiphospholipid antibodies. 

Marc Moghbel et al (Italy, Switzerland)

13.30-13.40

Comparative analysis of different ELISA assays for determination of aPL antibodies.

Violeta Dopsaj (Serbia)

13.40-13.50

Targeting plasma cells: New APS therapy aimed to resetting humoral immune memory.

Antonio Serrano (Spain)

13.50-14.00

Anticardiolipin antibodies and Anti-beta 2 glycoprotien 1: a comparative analysis from two centres with added value of antiprothrombin antibodies.

Marija Atanaskovic Popovic et al. (Serbia, Slovenia)

14.00-14.10

CLOSING REMARKS

14.10-15.10     SCIENTIFIC SESSION 3: RHEUMATIC DISEASE AND COVID‐ 19: INITIAL DATA

Moderators: Shoenfeld Y (Israel), Wahl D (France)

KEYNOTE LECTURES

14.10-14.30

Covid 19 the virus of autoimmunity –how it is related to APS?

Yehuda Shoenfeld (Israel)

14.30-14.50

APS and Covid-19, a critical review.

Denis Wahl (France)

ABSTRACT PRESENTATION

14.50-15.00

Preliminary Estimation of the COVID-19 in Systemic Lupus and Other Rheumatic Disease: Therapeutics Response in Stable Disease Condition.

Ljudmila Stojanovich et al (Serbia)

15.00-15.10

β-2-Glycoprotein-I deficiency could precipitate an antiphospholipid syndrome-like in COVID-19 patients.

Manuel Serrano on behalf of APS-COVID 19 Study Group/European Forum on aPL. (Spain)

15.10-15.25

The Covid-19 vaccine aspect and thrombosis

Pier-Luigi Meroni, Wahl Denis, Marteen Limper

15.25-16.10

LUNCH BREAK

16.10-17.30 SCINTIFIC SESSION 4: OBSTETRICAL APS/VASCULAR APS

Moderators: Angela Tincani (Italy), Elisabet Svenungsson (Sweden), Marija Zdravkovic (Serbia)

KEYNOTE LECTURES

16.10-16.30

The role of complement as predictor of adverse pregnancy outcome in obstetric APS.

Angela Tincani (Italy)

16.30-16.50

Complement deposition, C4d, on platelets is associated with vascular events and antiphospholipid antibodies in systemic lupus erythematosus.

Elisabet Svenungsson (Sweden)

ABSTRACT PRESENTATION

16.50-17.00

aPL Prevalence in Women with Late Pregnancy Complication and Low-risk for Chromosomal Abnormalities

Silvia Foddai et al (Italy) 

17.00-17.10

Thrombotic risk assessment in antiphospholipid syndrome using thrombin generation assay.

Barinotti A (Italy)

17.10-17.20

Cardiac MRI in patients with autoimmune rheumatic diseases.

Marija Zdravkovic (Serbia)

17.20-17.30

Early diagnosis of antiphospholipid syndrome in patients with subclinical manifestation -Radiology perspective.

Jovica Saponjski (Serbia)

17.30-17.40

Effects of CSF from CNS SLE patients on neuronal calcium signaling.

Milosevic M et al. (Serbia, Canada)

17.30-18.00     Closing remarks on the 12th MEETING OF THE EUROPEAN FORUM ON ANTIPHOSPHOLIPID ANTIBODIES
  • Denis Wahl (France): General coordinator of the European Forum.
  • Ricard Cervera (Spain): The former General coordinator of the European Forum.
  • Aleksandra Djokovic (Serbia): President of the National Organizing Committee
  • Ljudmila Stojanovich (Serbia): Congress President
POSTER PRESENTATIONS
  1. Asymmetric dimethylarginine is the marker of endothelial dysfunction in APS patients. Stanisavljevic N, Stojanovich L, Djokovic A, Dopsaj V, Todic B, Bisenic V, Marisavljevic M. (Serbia).
  2. APS/PT in obstetric APS: beyond early miscarriages and pregnancy loss. Daniel E. Pleguezuelo (Spain).
  3. Obstetrical outcome and treatments during pregnancy in seronegative primary APS: data from European retrospective study. Arsène Mekinian (France).
  4. Anti phosphatidylserine-prothrombin antibodies and lupus anticoagulant identify different types of APS-patients: the added value of anti fosfatidylserine-protrombine determination. Cabrera-Marante, M. Serrano D. Pleguezuelo et all. (Spain).
  5. Predictors of avascular bone necrosis in antiphospholipid syndrome. Seredavkina N.V. (Russian Federation).
  6. Mental disorders in antiphospholipid syndrome patients. Borisova A.B., Lisitsyna T.A., Veltishchev D.Yu., Reshetnyak T.M. (Russian Federation ).
  7. No-criteria antiphospholipid autoantibodies in a patient who suffered myocardial infarction. Amalia Tejeda-Velarde, Lourdes Villalobos, Irene Amil Casas, Patricia Morán Álvarez (Spain).
  8. Comparison of QUANTA lite and Euroimmun ELISA commercial kits in the detection of autoantibodies to cardiolipin and beta2glycoprotein.). Mrdakovic D, Milinkovic N, Stojanovich Lj, Stanisavljevic N, Dopsaj V. Mrdakovic D, Milinkovic N, Stojanovich Lj, Stanisavljevic N, Dopsaj V. (Serbia)

SPONSORS